Evidence map›Paper›PMID 40570160›Full record

ArticleJournal of veterinary internal medicine

Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis.

Sienna L Mitman, Danielle A Mzyk, Blanca E Camacho, R McAlister Council-Troche, Jennifer Davis, Derek M Foster, Jennifer Halleran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sienna L MitmanNorth Carolina State University, College of Veterinary Medicine, Raleigh, North Carolina, USA.
Danielle A MzykNorth Carolina State University, College of Veterinary Medicine, Department of Population Health and Pathobiology, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0002-9834-2089
Blanca E CamachoNorth Carolina State University, College of Veterinary Medicine, Raleigh, North Carolina, USA.ORCID https://orcid.org/0009-0007-1406-0409
R McAlister Council-TrocheVirginia-Maryland Regional College of Veterinary Medicine, Department of Biomedical Sciences and Pathobiology, Blacksburg, Virginia, USA.
Jennifer DavisVirginia-Maryland Regional College of Veterinary Medicine, Department of Biomedical Sciences and Pathobiology, Blacksburg, Virginia, USA.ORCID https://orcid.org/0000-0002-7930-4589
Derek M FosterNorth Carolina State University, College of Veterinary Medicine, Department of Population Health and Pathobiology, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0002-6859-9801
Jennifer HalleranNorth Carolina State University, College of Veterinary Medicine, Department of Population Health and Pathobiology, Raleigh, North Carolina, USA.ORCID https://orcid.org/0000-0002-1733-6307

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhenazopyridine is used for ancillary pain management in the treatment of goats with obstructive urolithiasis. However, there are no published studies on the pharmacokinetics, safety, or efficacy of phenazopyridine in goats. HYPOTHESIS/

objectivesDetermine the pharmacokinetic parameters of phenazopyridine after oral administration in goats with obstructive urolithiasis after tube cystostomy surgery. ANIMALS: Six male goats, ages 3 months to 4 years.

methodsProspective, observational study. Goats presenting to a veterinary institution diagnosed with obstructive urolithiasis underwent a tube cystostomy surgery. After surgery, phenazopyridine (4 mg/kg PO q12h) was administered. Plasma and urine samples were collected at predetermined intervals, and the concentration of phenazopyridine and clinically relevant metabolites was determined using ultra high-performance liquid chromatography with mass spectrometry. The pharmacokinetic parameters were determined using non-compartmental analysis.

resultsThe harmonic mean terminal elimination plasma half-life (T CONCLUSIONS AND CLINICAL IMPORTANCE: Phenazopyridine was rapidly eliminated from plasma and did not concentrate at detectable levels in the urine after oral administration.

Indexed as

Goat DiseasesPhenazopyridineUrolithiasisAdministration, OralAnimalsArea Under CurveGoatsHalf-LifeMaleProspective StudiesPhenazopyridineanalgesiacaprinepharmacologyurolithiasis

Identifiers

PMID40570160
PMCPMC12199991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.